Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 246 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Iron therapy Clear all
Completed No phase listed Observational

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

NCT00888316
View directory record Official record
Conditions
Cancer, Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation
Interventions
magnetic resonance imaging, Serum ferritin
Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Not applicable Interventional

Iron Depletion Therapy for Type 2 DM and NAFLD

NCT00230087
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions
blood donation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 4, 2026, 10:28 PM EDT
Enrolling by invitation No phase listed Observational

Effects of Social Determinants of Health on IV Iron Treatments

NCT06591182
View directory record Official record
Conditions
Social Determinants of Health (SDOH)
Interventions
Survey using a questionnaire.
Other
Lead sponsor
BayCare Health System
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

NCT02631733
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Ferumoxytol, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Veliparib
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Iron Depletion and Replacement in Blood Donors

NCT01752413
View directory record Official record
Conditions
Anemia
Interventions
Ferrous gluconate 325mg, Nutrition counseling
Dietary Supplement · Behavioral
Lead sponsor
Memorial Blood Centers, Minnesota
Other
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat, rhEPO, Ferrous sulfate containing the stable iron isotope (57Fe), Ferrous sulfate containing the stable iron isotope (58Fe)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Fort Worth, Texas • Lufkin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 4 Interventional Results available

Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia

NCT01904864
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
elemental iron (NovaFerrum®), elemental iron (Ferrous Sulfate)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
9 Months to 48 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Sep 4, 2026, 10:28 PM EDT
Recruiting Phase 2Phase 3 Interventional

IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study

NCT07217873
View directory record Official record
Conditions
Scoliosis Correction, Iron Deficiency, Transfusion Blood, Surgery Complications, Spinal Fusion, Scoliosis Idiopathic Adolescent, Scoliosis Neuromuscular
Interventions
Ferric carboxymaltose IV, Normal Saline (Placebo)
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 19 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 4, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)

NCT03409107
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat (GSK1278863), Placebo, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
49
States / cities
Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

NCT01186419
View directory record Official record
Conditions
Transfusional Iron Overload, Beta-thalassemia
Interventions
SPD602 (FBS0701, SSP-004184)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 60 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 4, 2026, 10:28 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of Ferumoxytol for the Treatment of Iron Deficiency Anemia in Pediatric Participants With Chronic Kidney Disease

NCT01155375
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, Oral Iron
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

NCT02680756
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Inflammatory Bowel Disease, Crohn's Disease
Interventions
Ferric Maltol, Ferric Carboxy Maltose
Drug
Lead sponsor
Shield Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
17
States / cities
Dothan, Alabama • Tucson, Arizona • Gainesville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

NCT00061750
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 4, 2026, 10:28 PM EDT
Enrolling by invitation Phase 4 Interventional

Nanozymes in Endodontics

NCT07518901
View directory record Official record
Conditions
Apical Periodontitis, Endodontic Disease, Root Canal Infection
Interventions
Nanozyme treatment, Control (Standard treatment)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 4, 2026, 10:28 PM EDT
Recruiting Phase 4 Interventional

Oral Iron in Children With Chronic Kidney Disease

NCT03991169
View directory record Official record
Conditions
Chronic Kidney Insufficiency, Chronic Kidney Diseases
Interventions
Ferrous Sulfate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Year to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 4, 2026, 10:28 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia

NCT06366698
View directory record Official record
Conditions
Iron Deficiency Anemia of Pregnancy
Interventions
Venofer 200 MG Per 10 ML Injection, Ferrous sulfate
Drug
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 4, 2026, 10:28 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Helicobacter Pylori and Body Iron in Adults

NCT03146325
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE, MATCHING PLACEBO
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 4, 2026, 10:28 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 4 Interventional Results available

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

NCT00224055
View directory record Official record
Conditions
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions
Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 4, 2026, 10:28 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndrome
Interventions
Deferasirox, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 4, 2026, 10:28 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

NCT02694978
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferumoxytol, FCM
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 4, 2026, 10:28 PM EDT